item management s discussion and analysis of financial condition and results of operations results of operations the following discussion and analysis should be read in conjunction with the company s financial statements and related notes appearing elsewhere in this report 
consolidated net income for was million compared to million in and million in diluted earnings per share increased from in and in to in for the year ended  shares outstanding on a diluted basis were million  up from million for the years ended and the change in diluted average shares outstanding from to is attributable to the increase in the number of in the money stock options included in the diluted average shares outstanding calculation following an appreciation in the price of the company s common stock during the second half of as well as common stock repurchases 
revenues consolidated revenues in totaled million  representing an increase of over revenues of million  which were over revenues of million 
inovoject r revenues totaled million in compared to million in and million in  representing increases of from to  and from to  with the increase coming principally from increased placement and throughput of inovoject r systems in north america and europe 
the revenues include inovoject r lease fees derived from multi year contracts and paid trials in the united states and foreign countries  and the sale of inovoject r systems to distributors 
embrex estimates that as of december   it was vaccinating in excess of of the estimated billion broiler birds grown in the united states in  and given its market penetration  the company expects only moderate inovoject r systems revenue growth in this market 
management anticipates moderate revenue and earnings growth in from existing inovoject r operations in the united states and canada  new inovoject r system leases in other countries  and sales of bursaplex r product to poultry producers worldwide 
however  the rate at which the marketplace will accept the inovoject r technology outside the united states and canada  the timing of regulatory approvals of third party vaccines for in ovo use outside the united states and canada  start up costs in new markets  possible variability in united states hatchery bird production as a result of grain price fluctuations  and variability in the demand for  and pricing of  us poultry and poultry products outside the united states  will impact the pace of revenue growth  if any  and the sustaining of profitability from the installation and operational throughputs of inovoject r systems 
sales of bursaplex r  the company s proprietary vaccine for the treatment of avian infectious bursal disease  was the principal source of million of product revenues in and  of product revenues in the company s ability to generate revenue from product sales has been constrained by the previously announced delay associated with ft 
dodge s obtaining british regulatory approval for the sale of bursamune r in the united kingdom  lower levels of breeder and broiler flock vaccination rates  and fewer reported incidences of bursal disease in the united states 
product sales increased during from the  recorded for the same period in sales of vnf r for inclusion in ibd vaccines were the principal source of previous years product revenues  which generated million and million in and  respectively 
cost of product sales and inovoject r revenues cost of revenues as a percentage of revenues decreased from and of total revenues in and  respectively  to of total revenues in the improvement in is primarily attributable to inovoject r system related cost reductions and some price increases in selected markets 
operating expenses operating expenses totaled million in compared to million in  and million in general and administrative g a expenses were million in  up from million in  and up from million in the and g a increases over were primarily attributable to development costs in asia and latin america as well as legal expenses incurred in connection with various patent infringement lawsuits filed by the company 
sales and marketing expenses totaled  in compared to  in and  in fluctuations during these periods resulted from various levels of activity in the company s sales and customer service functions to support market expansion and field support of inovoject r systems  as well as stepped up international activity  principally in europe 
certain operating expenses were reclassified to cost of revenues to conform to the presentation 
these reclassifications had no effect on previously reported net income or shareholders equity 
research and development r d expenses were million in compared to million in and million in the increase in r d expense from to largely reflects an increase in outside contract research  supplies consumption  operating expenses for the new research facility and inovoject r design and development and global technical support activity 
the company continues to manage its research and development effort to leverage its know how  patent position  market presence and expenditures 
other income and expense interest income totaled   and  in years  and  respectively 
the decrease relative to resulted principally from lower cash balances and the decrease relative to resulted principally from lower cash balances and lower interest rates 
interest expense totaled  in compared to  in and million in in  the decrease in interest expense reflected the repayment of approximately million of external financing  primarily in the form of equipment leases 
in  the decrease in interest expense reflected the repayment of approximately million of external financing  primarily in the form of equipment leases 
in  the amount of interest expense was principally attributable to the company s funding of its growing installed base of inovoject r systems with the use of capital lease financing 
management expects to continue to rely on the use of internally generated funds to finance the cost of additional inovoject r systems in  as was the case in effect of inflation management expects cost of product sales and inovoject r systems revenues  operating expenses and capital equipment costs to change in line with periodic inflationary changes in price levels 
while management generally believes that the company will be able to offset the effect of price level changes by adjusting selling lease prices and effecting operating efficiencies  any material unfavorable changes in price levels could have a material adverse affect on its results of operations 
liquidity and capital resources at december   the company s cash and short term investment balances totaled million compared to million and million at december  and  respectively 
the decrease reflected the ability of the company to fund capital expenditures with internal cash instead of equipment lease financing 
working capital decreased to million in from million in  as a decrease in cash was offset by a reduction in the short term portions of capital lease obligations 
during  operating activities generated million in cash  primarily due to non cash depreciation and net income 
within investing activities  inovoject r systems  the company s new research facility  and equipment purchases required million 
financing activities used million  of which million was used to repay long term debt and capital lease obligations and million was used to repurchase the company s common stock see below 
in october  the company announced that the board of directors authorized a share repurchase program to purchase up to of outstanding shares of common stock  or up to approximately  shares over months  in open market or privately negotiated transactions 
as of december   the company had purchased  shares for million at an average price of 
see notes to consolidated financial statements 
as of december   the company had outstanding purchase commitments of approximately million related to the production of the company s bursaplex r product  vnf r for the manufacture of bursaplex r and bursamune r  and materials and supplies for construction and maintenance of inovoject r egg injection systems 
the company maintained during a million secured line of credit with a bank in the united kingdom  which could be used to finance the construction of additional inovoject r systems for europe  the middle east and africa 
the company utilized million of this line during this line of credit was repaid and terminated by year end in april  the company obtained a million secured revolving line of credit from its bank  branch banking and trust company 
this line of credit may be used for working capital purposes and has a term of months 
based on its current operations  management believes that the company s available cash and short term investments  together with cash flow from operations  will be sufficient to meet its foreseeable cash requirements 
year issue the company established a team to address the year issue in june the team conducted an inventory and assessment of the company s computer hardware and software systems  as well as embedded systems in its inovoject r systems  manufacturing and laboratory equipment and office facilities 
the team developed remediation  testing  and implementation plans for imbedded systems  including the inovoject r system  which remediation  testing  and implementation was completed in october the company also engaged an outside consulting firm to conduct an independent verification and validation of the controls and software that operate the inovoject r system  which determined that the inovoject r system was not affected by year considerations 
the company incurred approximately  in addressing year issues 
to date  the company is not aware of any immediate  adverse impact resulting from year issues  either on the company s ability to operate and manage the inovoject r system at its customers hatcheries or its ability to manage its business and to communicate with its customers and suppliers 
however  the company cannot provide any assurance that its systems and business relationships have not been impacted in a manner that is not yet apparent 
the company will continue to monitor its systems in order to promptly remediate any adversely impacted systems 
forward looking statements information set forth in this annual report on form k contains various forward looking statements within the meaning of section a of the securities act of and section e of the securities exchange act of  which statements represent the company s judgment concerning the future and are subject to risks and uncertainties that could cause the company s actual operating results and financial position to differ materially 
such forward looking statements can be identified by the use of forward looking terminology such as may  will  expect  anticipate  estimate  believe  or continue  or the negative thereof or other variations thereof or comparable terminology 
the company cautions that any such forward looking statements include statements with respect to future products  services  markets and financial results 
these statements involve risks and uncertainties that could cause actual results to differ materially  including without limitation the ability of the company to penetrate new markets  place inovoject r systems worldwide  establish a degree of market acceptance for new products such as but not limited to bursaplex r and bursamune r  prevail in the outcome of its patent litigation appeal  the number of eggs set by poultry producers  complete commercial development of potential future products or obtain regulatory approval of its products  which approval is dependent upon a number of factors  such as results of trials  the discretion of regulatory officials  and potential changes in regulations  and the company s dependence on certain customers 
these statements are also contingent upon continued growth and production levels of the global poultry industry and the economic viability of certain markets 
additional information on these risks and other factors which could affect the company s financial results are included in the risk factors described in exhibit to this report and in the company s other filings with the sec  including the company s forms q  k and k 
item a 
quantitative and qualitative disclosures about market risk a portion of the company s operations are in jurisdictions outside north america 
the company leases inovoject r systems and sells products in europe  asia  and latin america 
as a result  the company s financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which the company distributes its products 
at december   the company s operations outside north america were not material to the company s consolidated results as a whole  and a significant change in currency exchange rates or economic conditions in the jurisdictions outside north america in which the company operates would not have a material effect on the company s consolidated financial results 

